| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Due to the limitations of liver biopsy and currently available noninvasive imaging techniques, new noninvasive approaches for diagnosis of liver diseases, especially the most common subgroup fatty liver disease (FLD), have become an urgent requirement. In this study, we focused on the mitochondrial dysfunction that is responsible for disease progression of FLD, and translocator protein (18 kDa)(TSPO)-a mitochondrial transmembrane protein, explored whether TSPO can be used as an imaging biomarker of noninvasive diagnosis and staging of FLD, monitored using PET with a TSPO specific radioligand [18F]FEDAC. Our data demonstrated TSPO is a good imaging biomarker, and [18F]FEDAC-PET can accurate and noninvasive diagnosis and staging of FLD with excellent sensitivity and specificity. Our study may open a novel avenue for noninvasive and reliable clinic screening of FLD focusing on the general population.
|
